HUP0000145A3 - Betha-sulfonyl hydroxamic acid derivatives with matrix maetalloproteinases inhibitor activity, use thereof and pharmaceutical compositions containing them - Google Patents

Betha-sulfonyl hydroxamic acid derivatives with matrix maetalloproteinases inhibitor activity, use thereof and pharmaceutical compositions containing them

Info

Publication number
HUP0000145A3
HUP0000145A3 HU0000145A HUP0000145A HUP0000145A3 HU P0000145 A3 HUP0000145 A3 HU P0000145A3 HU 0000145 A HU0000145 A HU 0000145A HU P0000145 A HUP0000145 A HU P0000145A HU P0000145 A3 HUP0000145 A3 HU P0000145A3
Authority
HU
Hungary
Prior art keywords
maetalloproteinases
betha
matrix
pharmaceutical compositions
compositions containing
Prior art date
Application number
HU0000145A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of HUP0000145A2 publication Critical patent/HUP0000145A2/hu
Publication of HUP0000145A3 publication Critical patent/HUP0000145A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Lubricants (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HU0000145A 1996-09-27 1997-09-19 Betha-sulfonyl hydroxamic acid derivatives with matrix maetalloproteinases inhibitor activity, use thereof and pharmaceutical compositions containing them HUP0000145A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2684896P 1996-09-27 1996-09-27
PCT/US1997/016348 WO1998013340A1 (en) 1996-09-27 1997-09-19 β-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS

Publications (2)

Publication Number Publication Date
HUP0000145A2 HUP0000145A2 (en) 2000-07-28
HUP0000145A3 true HUP0000145A3 (en) 2001-12-28

Family

ID=21834136

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0000145A HUP0000145A3 (en) 1996-09-27 1997-09-19 Betha-sulfonyl hydroxamic acid derivatives with matrix maetalloproteinases inhibitor activity, use thereof and pharmaceutical compositions containing them

Country Status (21)

Country Link
US (2) US5847153A (enExample)
EP (1) EP0929519B1 (enExample)
JP (1) JP2001516338A (enExample)
KR (1) KR20000048639A (enExample)
CN (1) CN1158254C (enExample)
AT (1) ATE289590T1 (enExample)
AU (1) AU726799B2 (enExample)
BR (1) BR9712134A (enExample)
CA (1) CA2266368A1 (enExample)
CZ (1) CZ92399A3 (enExample)
DE (1) DE69732571T2 (enExample)
EA (1) EA001460B1 (enExample)
ES (1) ES2236829T3 (enExample)
HU (1) HUP0000145A3 (enExample)
ID (1) ID21897A (enExample)
IL (1) IL128900A0 (enExample)
NO (1) NO312893B1 (enExample)
NZ (1) NZ334729A (enExample)
PL (1) PL332509A1 (enExample)
UA (1) UA48262C2 (enExample)
WO (1) WO1998013340A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566384B1 (en) 1996-08-07 2003-05-20 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
CA2263154A1 (en) * 1996-08-07 1998-02-12 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
NZ334729A (en) 1996-09-27 2001-01-26 Upjohn Co 'Beta'-sulfonyl hydroxamic acids as matrix metalloproteinase inhibitors involved in tissue degradation
PT960096E (pt) 1997-01-22 2005-08-31 Aventis Pharma Inc Acidos beta-tiocarboxilicos substituidos
GB9702088D0 (en) 1997-01-31 1997-03-19 Pharmacia & Upjohn Spa Matrix metalloproteinase inhibitors
US6172057B1 (en) 1997-02-27 2001-01-09 American Cyanamid Company N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
WO1998039326A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
CN1254337A (zh) * 1997-03-04 2000-05-24 孟山都公司 N－羟基4－磺酰基丁酰胺化合物
US6063786A (en) * 1997-11-12 2000-05-16 Darwin Discovery, Ltd. Heterocyclic compounds having MMP and TNF inhibitory activity
US6187924B1 (en) * 1997-11-12 2001-02-13 Darwin Discovery, Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
TR200001391T2 (tr) * 1997-11-21 2000-11-21 Pharmacia & Upjohn Company Matris metaloproteinaz önleyicileri olarak beta-sülfonil hidroksamik asitlerin alfa-hidroksi, -amino ve halo türevleri.
US6100266A (en) * 1998-01-30 2000-08-08 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
ES2310636T3 (es) 1998-06-18 2009-01-16 F. Hoffmann-La Roche Ag Proceso para sulfuros de arilalquilo.
GB9916562D0 (en) 1999-07-14 1999-09-15 Pharmacia & Upjohn Spa 3-Arylsulfonyl-2-(substituted-methyl) propanoic acid derivatives as matrix metalloproteinase inhibitora
US6620823B2 (en) * 2000-07-11 2003-09-16 Bristol-Myers Squibb Pharme Company Lactam metalloprotease inhibitors
GB0017435D0 (en) * 2000-07-14 2000-08-30 Pharmacia & Upjohn Spa 3-arylsulfonyl-2-hydroxy-2-methylpropanoic acid derivatives
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
ATE457716T1 (de) 2002-12-30 2010-03-15 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
JP2009519349A (ja) * 2005-12-15 2009-05-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を変調する化合物
JP5448164B2 (ja) 2006-07-28 2014-03-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を変調する化合物
US7928123B2 (en) 2006-09-25 2011-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
EP2217565B1 (en) * 2007-11-07 2013-05-22 Boehringer Ingelheim International GmbH Compounds which modulate the cb2 receptor
JP5749162B2 (ja) * 2008-07-10 2015-07-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節するスルホン化合物
AP2011005674A0 (en) 2008-09-25 2011-04-30 Boehringer Ingelheim Int Sulfonyl compounds which selectively modulate the CB2 receptor.
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
EP2443107B1 (en) 2009-06-16 2018-08-08 Boehringer Ingelheim International GmbH Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor
JP2013505295A (ja) * 2009-09-22 2013-02-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を選択的に調節する化合物
EP2523936A1 (en) 2010-01-15 2012-11-21 Boehringer Ingelheim International GmbH Compounds which modulate the cb2 receptor
EP2542539B1 (en) 2010-03-05 2014-02-26 Boehringer Ingelheim International GmbH Tetrazole compounds which selectively modulate the cb2 receptor
US8846936B2 (en) 2010-07-22 2014-09-30 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the CB2 receptor
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB689608A (en) * 1950-04-13 1953-04-01 Basf Ag Improvements in the production of gamma-sulphonyl carboxylic acids
US2659752A (en) * 1951-08-09 1953-11-17 Goodrich Co B F Method for preparing beta-(arylsulfonyl) carboxylic acids and salts thereof
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
EP0634998B1 (en) * 1992-04-07 1997-03-19 British Biotech Pharmaceuticals Limited Hydroxamic acid based collagenase and cytokine inhibitors
DE4233100A1 (de) * 1992-10-01 1994-04-07 Hoechst Ag Verfahren zur stereoselektiven Synthese von 3-substituierten 2-Sulfonylmethylpropionsäuren sowie Zwischenprodukte
DE4233099A1 (de) * 1992-10-01 1994-04-07 Hoechst Ag Verfahren zur stereoselektiven Synthese von 3-substituierten 2-Thiomethylpropionsäuren
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
EP0640594A1 (en) * 1993-08-23 1995-03-01 Fujirebio Inc. Hydantoin derivative as metalloprotease inhibitor
GB9320660D0 (en) * 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
DE69624081T2 (de) * 1995-12-20 2003-06-12 Agouron Pharmaceuticals, Inc. Matrix-metalloprotease Inhibitoren
PT871439E (pt) * 1996-01-02 2004-08-31 Aventis Pharma Inc Compostos do acido hidroxamico substituidos (arilo heteroarilo arilmetilo ou heteroarilmetilo)
TW448172B (en) * 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
NZ334729A (en) * 1996-09-27 2001-01-26 Upjohn Co 'Beta'-sulfonyl hydroxamic acids as matrix metalloproteinase inhibitors involved in tissue degradation
WO1998039326A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds

Also Published As

Publication number Publication date
CZ92399A3 (cs) 1999-07-14
CN1230177A (zh) 1999-09-29
AU4645997A (en) 1998-04-17
CA2266368A1 (en) 1998-04-02
JP2001516338A (ja) 2001-09-25
EP0929519A1 (en) 1999-07-21
DE69732571T2 (de) 2006-01-12
US6235928B1 (en) 2001-05-22
EA199900332A1 (ru) 1999-12-29
NO991494L (no) 1999-05-26
DE69732571D1 (de) 2005-03-31
NO312893B1 (no) 2002-07-15
NZ334729A (en) 2001-01-26
CN1158254C (zh) 2004-07-21
HK1022468A1 (en) 2000-08-11
IL128900A0 (en) 2000-01-31
UA48262C2 (uk) 2002-08-15
KR20000048639A (ko) 2000-07-25
PL332509A1 (en) 1999-09-13
NO991494D0 (no) 1999-03-26
HUP0000145A2 (en) 2000-07-28
WO1998013340A1 (en) 1998-04-02
ATE289590T1 (de) 2005-03-15
BR9712134A (pt) 1999-08-31
EP0929519B1 (en) 2005-02-23
ES2236829T3 (es) 2005-07-16
AU726799B2 (en) 2000-11-23
ID21897A (id) 1999-08-05
US5847153A (en) 1998-12-08
EA001460B1 (ru) 2001-04-23

Similar Documents

Publication Publication Date Title
HUP0000145A3 (en) Betha-sulfonyl hydroxamic acid derivatives with matrix maetalloproteinases inhibitor activity, use thereof and pharmaceutical compositions containing them
HUP0100152A3 (en) Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity, pharmaceutical compositions containing them and their use
HUP9903687A3 (en) Arylsulfonylamino carboxylic and hidroxamic acid derivatives and pharmaceutical compositions with metalloproteinase inhibitory activity containing them
NZ304689A (en) Lactam-containing hydroxamic acid derivatives and use as matrix metalloprotease (mmp) inhibitors
HUP0000567A3 (en) Sulfonyl urea derivatives and pharmaceutical compositions thereof inhibiting interleukin-1 activity
IL138028A0 (en) Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical use
HUP0000965A3 (en) Pyrrolidine derivatives having phospolipase a2 inhibitory activity and pharmaceutical compositions containing the same
NZ231508A (en) Hydroxamic acid derivatives, pharmaceutical compositions and intermediate compounds
HUP0100101A3 (en) Prostaglandin agonists, pharmaceutical compositions comprising thereof and their use
NZ298677A (en) Hydroxamic acid derivatives, preparation and pharmaceutical compositions thereof
IL135177A0 (en) Amidocarboxylic acid derivatives and pharmaceutical compositions containing the same
HUP0103793A3 (en) N-(2-aryl-propionyl)-sulfonamids, their use and pharmaceutical preparations containing them
HUP0100178A3 (en) Tetrahydro-naphtiridinyl-imidazolydinyl-carboxylic acid derivatives and pharmaceutical compositions thereof
PT1213020E (pt) Compostos e composições farmacêuticas com actividade supressora do apetite
HUP0004845A3 (en) Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist activity to ppar-gamma and pharmaceutical compositions containing them
IL129149A (en) beta-SULFONAMIDO HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS, COMPOSITIONS CONTAINING THEM AND THEIR USE
HUP0000969A3 (en) Heterocyclic esters and amides, their use and pharmaceutical compositions containing them
EP1024130A4 (en) BIPHENYL-5-ALKANIC ACID DERIVATIVES AND THEIR USE
HUP0102766A3 (en) Aminomethylcarboxylic acid derivatives, their pharmaceutical use and pharmaceutical compositions comprising them
HUP0200386A3 (en) Nitroxyderivatives having antiinflammatory, analgesic and antithrombotic activity and pharmaceutical compositions containing them and their use
HUP9904694A3 (en) Spiropyrrolidine derivatives, their use and pharmaceutical compositions containing them
IL134536A0 (en) Compounds possessing neuronal activity and pharmaceutical compositions containing the same
HUP9801227A3 (en) Pharmaceutical compositions comprising monoamine oxidase b inhibitors and their use
HUP9904682A3 (en) Phenyloxazole and -thiazole derivatives, their use and pharmaceutical compositions containing them
HUP0002853A3 (en) 6,7-asymmetrically disubstituted quinoxalinecarboxylic acid derivatives, and pharmaceutical compositions containing them